Contraception in patients at risk for thromboembolism;CONTRACEPTION DES MALADIES A RISQUE THROMBOEMBOLIQUE

Sang Thrombose Vaisseaux

Volumn 8, Issue 2, 1996, Pages 101-105

  Gompel, Anne ^a   Chabbert Buffet, Nathalie ^a   Poitout, Philippe ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT;

CONDOM; CONTRACEPTIVE DEVICE; ORAL DRUG ADMINISTRATION; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 0029991966     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Gompel A. Contraception, in : Godeau P, Piette JC, éds. Traité de médecine. Paris: Flammarion, Médecine Sciences, 1996 (sous presse).
2. Saey A, Vanderick G, De Muylder D. Étude par ordinateur de 1 161 cas de traitement continu au lynestrenol 5mg. Ars Med 1976; 31 : 1809-53.
3. Clarkson TB, Anthony MS, Klein KP. Effects of estrogen treatment on arterial wall structure and function. Drugs 1994;47(suppl. 2): 42-51.
4. Pines A, Fisman EZ, Levo Y, et al. The effects of hormone replacement t therapy in normal postmenopausal I women : measurements of Dopplerderived parameters of aortic flow. Am J Obst Gynecol 1991 ; 164: 806-12.
5. Gangar KF, Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation to transdermal estradiol and time since menopause. Lancet 1991 ; 338: 839-42.
6. Engel HJ, Enjel E, Lichtlen PR. Coronary atherosclerosis and myocardial infarction in young women. Role of oral contraceptives, Eur Heart J 1983 ; 4: 1-0.
7. Gerstman BB, Piper JM, Tomita DK, Ferquson WJ, Stadel BV, Lundin F. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7.
8. Kay J. The Royal College of General Practitionner's. Oral contraception study. Clin Obstet Gynecol 1984; 11 : 759-85.
9. Lidegaard O. Oral contraceptives and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 1993; 306: 956-963.
10. Basdevant A, Conard J, Denis C, Guyene T, Egloff M, Denys I. Effets métaboliques et hormonaux de l'administration de 1 mg/24 h de promegestone (RU 5020). Gynecologie 1989; 40(suppl. 2); 17-21.
11. Basdevant A, Pelissier C, Conard J, Degrelle H, Guyene TT, Thomas JL. Effects of nomegestrol acetate (5mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991; 44: 599-605.
12. Basdevant A, Bricaire C, Gompel A, et al. Effects of cyproterone acetate on blood pressure, metabolic parameters and haemostasis in hirsute women. Fertil Steril 1996(sous presse).
13. Pelissier C, Caby J. Contraception des femmes à haut risque vasculaire et métabolique. Gynecoloqie 1983 ; 34 : 131-8.
14. Gompel A, Pelissier C, Kuttenn F, et al. Hormones et lupus. Rev Med Intern 1985 ; 6: 543-52.
15. Jungers P, Kuttenn F, Liotte F, et al. Hormonal modulation in systemic lupus erythematosus : preliminary clinical and hormonal results with cyproterone acetate. Arthritis Rheum 1985; 28: 1243-50.
16. Gompel A, Chabbert-Buffet N, Godeau P, Poitout Ph. Contraception in auto-immune diseases. In : Creatsas G, Serfaty D, Skouby S, eds. Proceedings of the third congress of the European Society of contraception. Athènes : ESC, 1994: 87-93.
17. e série, 1993: 125-30.
18. Kuttenn, Moufarege A, Mauvais-Jarvis P. Bases hormonales de la contraception progestative discontinue. Nouv Press Med 1978 ; 7: 3109-13.
19. Conard J, Cazenave B, Samama M, Horellou MH, Zorn JR, Neau C. AT III content and antithrombin activity in estrogen progestogen and progestogen only treated women. Thromb Res 1980; 18:675-81.
20. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side effects and influence on the activity of SLE. Scand J Rheum 1991 ; 20: 427-33.
21. Buhler M, Papiernik E. Successive pregnancies in women fitted with intra uterine devices who takes anti-inflammatory drugs. Lancet 1983; 2: 483.